Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax Ebola
- Development stage
- Unknown
- Lead developer
- Emergent BioSolutions
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intraperitoneal, Intranasal, Oral, Intravenous
01
Overview
VesiculoVax Ebola (also known as VesiculoVax Vectored EBOV Vaccine) is a mono-valent, replication-competent viral vector vaccine developed by Auro Vaccines in partnership with Emergent BioSolutions for the prevention of Ebola virus disease (EVD). The vaccine utilizes a highly attenuated recombinant vesicular stomatitis virus (rVSV) vector—the prototype of the VesiculoVax platform—engineered to express the Zaire ebolavirus glycoprotein (GP) as its active immunogen. Upon administration, the replication-competent vector activates the immune system through innate signals and the release of molecular adjuvants, triggering the rapid expansion of B cells and the production of protective antibodies. The platform is characterized by low pre-existing immunity in the human population compared to adenovirus-based vectors. Clinical evaluation has progressed through Phase 1, where the vaccine demonstrated safety, 100% vaccine take, and immunogenicity across a range of doses.
- Brand names
- VesiculoVax Ebola
- Other names
- VesiculoVax Vectored EBOV Vaccinemono-valent VSV-vectored Ebola vaccine
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on VesiculoVax Ebola.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax Ebola.